Hamaguchi, Tetsuya
Tsuji, Akihito
Yamaguchi, Kensei
Takeda, Koji
Uetake, Hiroyuki
Esaki, Taito
Amagai, Kenji
Sakai, Daisuke
Baba, Hideo
Kimura, Masami
Matsumura, Yasuhiro
Tsukamoto, Tetsuji
Article History
Received: 24 May 2018
Accepted: 24 September 2018
First Online: 4 October 2018
Compliance with ethical standards
:
: T. Hamaguchi has received research grants from Sumitomo Dainippon Pharma, Taiho Pharmaceutical, MSD, Teijin Pharma, Eli Lilly, Ono Pharmaceutical and Sanofi, honorariums from Novartis Pharma, Ono Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Yakult, and is a medical advisor for NanoCarrier. A. Tsuji has received honorariums from Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Serono, Takeda Pharmaceutical, and Bristol-Myers Squibb, and is speaker’s bureau for Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical and Merck Serono. K. Yamaguchi has received speaking honorariums from Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Serono, Takeda Pharmaceutical, Yakult, Bayer, Daiichi Sankyo, Ono Pharmaceutical, Eli Lilly, Sanofi, and Bristol-Myers Squibb, has received research grants from MSD, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Yakult, and has served on safety review committees for Bristol-Myers Squibb. K. Takeda has received research grants from Abbvie, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Serono, MSD, Ono Pharmaceutical, Pfizer and Taiho Pharmaceutical, and has received honorariums from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Novartis Pharma, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical. H. Uetake has received speaking honorariums from Taiho Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, Sanofi, and Eli Lilly. T. Esaki has received honorariums from Taiho Pharmaceutical, Eli Lilly, Merck Serono, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, and Daiichi Sankyo, and has received research grants from Daiichi Sankyo, MSD, Novartis Pharma, Sumitomo Dainippon Pharma, and Ono Pharmaceutical. K. Amagai has received grants from Taiho Pharmaceutical and MSD, and contributions. H. Baba has received speaking honorariums from Nippon Kayaku, Taiho Pharmaceutical, and Eli Lilly. T. Tsukamoto is an employee of Nippon Kayaku. The other authors have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.